Protocolo de Actuación en Mieloma múltiple - Sociedad Asturiana ...

BIBLIOGRAFIA
1. Beksac M, Haznedar R, Firatll T el al. Addition of thalidomide to oral MP in patients with
multiple myeloma and not eligible for transplantation: results of a randomized trial from the
Turkish Myeloma Study Group. Eur J Hematol 2011; 86: 16-22
2. Bied J, Owen R, D´Sa et al. (BCSH and UK Myeloma Forum) Guidelines for the diagnosed
and management of multiple myeloma 2011. Br J Haematol 2011: 154: 32-75
3. Facon T, Mary JY, Hulin C, et al. Intergroupe Francophone du Myélome. Melphalan
and prednisone plus thalidomide versus melphalan and prednisone alone or reducedintensity
autologous stem cell transplantation in elderly patients with multiple
myeloma (IFM 99-06): a randomised trial. Lancet 2007; 6;370:1209-18
4. Fayers P, Palumbo A, Hulin C et al. Thalidomide for previously untreated elderly patients
with multiple myeloma: meta-analysis of 1685 patients data from 6 randomized clinical trials.
Blood 2011; 118:1239-1247
5. Gay F, Larocca A and Wijermans P et al. Complete response correlates wtih long-term
progression-free and oerall myeloma treates with novel agents: analysis of 1175
patients. Blood 2011; 117: 3025-3031
6. Gulbrandsen N, Waage A, Gimsing P, Turesson I, Juliusson G, Ablidgaard N et al. A
randomised placebo controlled study with melphalan/prednisone/thalidomide: quality
of life and toxicity. Haematologica 2008; 93 (abst.0209).
7. Hulin C, Facon T, Rodon P et al. Melphalan-Prednisone-Thalidomide (MP-T)
Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with
Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized,
Double-Blind, Placebo-Controlled Trial, IFM 01/01. Blood 2007:110 (abst.75).
8. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, Egyed M, Spicka I,
Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A. Thalidomide-dexamethasone
compared with melphalan-prednisolone in elderly patients with multiple myeloma.
Blood 2009; 113:3435-42
9. Ludwig H, Durie B, McCarthy P et al. IMWG consensus on maintenance therapy in multiple
myeloma. Blood 2012; 119: 3003-3015
10. Mateos MV, Richardson PG, Schlag R et al. VMP compared MP in previously untreated
multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III
VISTA trial. J Clin Oncol 2010: 28: 2269-2266
11. Mateos MV, Oriol A, Martínez-López J et al. Bortezomib, melphalan and prednisone vs
Bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance
treatment with Bortezomib and thalidomide vs Bortezomib and prednisone and prednisone in
elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010; 11:
934-941
12. Mehta J, Cavo M and Singhal S. How I treat elderly patients with myeloma. Blood 2010
116:2215-2223
13. Morgan G, Davies F, Gregory W et al. CTD as initial therapy for patients with multiple
myeloma unsuitable for autologous transplantation. Blood 2011; 118: 1231-1228
Grupo Asturiano de Linfoma y Mieloma
53